XML 28 R17.htm IDEA: XBRL DOCUMENT v3.25.1
SUBSEQUENT EVENTS
3 Months Ended
Mar. 31, 2025
SUBSEQUENT EVENTS  
SUBSEQUENT EVENTS

10.

SUBSEQUENT EVENTS

Management has evaluated subsequent events through the date of issuance of these condensed consolidated financial statements and has determined that there are no subsequent events outside the ordinary scope of business that require adjustment to, or disclosure in, the condensed consolidated financial statements, other than those described below:

Receipt of $1.7 million from New Jersey Business Tax Certificate Program

On April 21, 2025, the Company announced that it received $1.7 million in cash proceeds from the sale of 2023 and amended 2022 Net Operating Loss (NOL) and R&D tax credits from the Technology Business Tax Certificate Transfer Program, sponsored by the New Jersey Economic Development Authority (NJEDA). The program allows technology and biotechnology businesses with net operating losses to turn their tax losses and credits into cash to buy equipment or facilities, or for other allowable expenditures. The Company amended its tax return for 2022 following the passage of New Jersey tax reform legislation, A.B. 5323, on July 3, 2023, containing provisions that retroactively allowed taxpayers in New Jersey to immediately deduct from research and experimental (R&E) expenditures for which state R&D credit is claimed. The legislation was retroactive to January 1, 2022. The Company intends to utilize the funding to help drive ongoing growth, including preparations for the anticipated launch of DrugSorb-ATR in the U.S. and Canada, scaling up manufacturing in the Princeton facility, and supporting other key strategic initiatives.